Mindset Pharma’s COPE Program Will Help Discover New Classes of Psychedelics NCEs

Mindset Pharma Inc. (CNSX: MSET)(OTCMKTS: MSSTF), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders, is trying its best to cope. That is, identifying new pharmacological insights related to the mechanisms of action and bioavailability of first generation psychedelics through its co-operative Psychedelics Evaluation Platform (COPE) program with InterVivo Solutions. COPE will establish a comprehensive psychedelics benchmark reference data set by evaluating a broad range of psychedelic drugs through a proprietary program of in vivo tests conducted at InterVivo’s facility. 

The program is Mindset Pharma’s way of establishing a robust methodology towards early-stage decision making by focusing on the key determinants of success. This is standard practice in the biopharma industry, including the multi-national conglomerate pharmaceutical companies that rely on internal programs to discover early-stage drug prospects. Mindset will be focusing its energy on novel psychedelic compounds which potentially have better efficacy and attributes (i.e. quicker offset times) to improve on what nature gave us.

The company is particularly focused on created New Chemical Entities (NCE) which are patentable unlike the original psychedelic compound itself. A NCE is referred to as either a new drug product or as a new drug substance. A new drug product is a pharmaceutical product type, such as tablets, capsules, solutions, creams, etc., which has not previously been registered in a region or Member State, and which contains a drug ingredient generally in association with excipients. The FDA defines new drug substances as new compounds produced by chemical syntheses and not
previously registered in a region or member state.

In this interview, Chief Scientific Officer Joe Araujo encapsulates just Mindset Pharma’s goes about developing its drug pipeline portfolio. It begins with getting the right foundation in place.

So I think, what we’re trying to do is develop new drugs that are superior to known drugs. And so, ir order to do that, you need to build a model system, right. So, if you were going to build a house, you can build a small model. So, when we’re trying to develop new drugs, we develop model systems to test those drugs is comparison to other drugs.

Click on the embedded link to view the complete Mindset interview with CEO James Lanthier and CSO Joe Araujo, in their own words.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More